LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

43.94 -1.61

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

43.03

Max

44.56

Galvenie mērījumi
By Trading Economics
Ienākumi	36M -2.3M
Pārdošana	-3.9M 208M
P/E Sektora vidējais	48.435 50.102
EPS	0.21
Peļņas marža	-1.104
Darbinieki	778
EBITDA	-72M 19M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+40.19% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2.1M 2.8B
Iepriekšējā atvēršanas cena	45.55
Iepriekšējā slēgšanas cena	43.94

Ziņu noskaņojums

By Acuity

14%

86%

17 / 344 Rangs Healthcare

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. jūn. 23:48 UTC

Tirgus saruna

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

2026. g. 1. jūn. 23:38 UTC

Iegādes, apvienošanās, pārņemšana

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

2026. g. 1. jūn. 23:37 UTC

Tirgus saruna

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

2026. g. 1. jūn. 23:01 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 1. jūn. 23:01 UTC

Tirgus saruna

Dexus Stuck in 'Too Hard' Basket -- Market Talk

2026. g. 1. jūn. 22:08 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026. g. 1. jūn. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026. g. 1. jūn. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

2026. g. 1. jūn. 21:55 UTC

Iegādes, apvienošanās, pārņemšana

Greg Abel's Week Is Off to Quite a Start -- WSJ

2026. g. 1. jūn. 21:53 UTC

Tirgus saruna

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

2026. g. 1. jūn. 21:22 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

2026. g. 1. jūn. 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 1. jūn. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 1. jūn. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 1. jūn. 20:46 UTC

Iegādes, apvienošanās, pārņemšana

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

2026. g. 1. jūn. 20:22 UTC

Iegādes, apvienošanās, pārņemšana

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

2026. g. 1. jūn. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

2026. g. 1. jūn. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Array Digital Infrastructure Declares $11 Special Div

2026. g. 1. jūn. 20:20 UTC

Iegādes, apvienošanās, pārņemšana

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

2026. g. 1. jūn. 19:40 UTC

Tirgus saruna

Remittances to Mexico Rise for Third Straight Month -- Market Talk

2026. g. 1. jūn. 19:28 UTC

Tirgus saruna

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

2026. g. 1. jūn. 19:01 UTC

Tirgus saruna

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

2026. g. 1. jūn. 18:58 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

2026. g. 1. jūn. 18:54 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

2026. g. 1. jūn. 18:33 UTC

Tirgus saruna

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

2026. g. 1. jūn. 18:32 UTC

Tirgus saruna

Precious Metals Fall to Start June -- Market Talk

2026. g. 1. jūn. 18:00 UTC

Iegādes, apvienošanās, pārņemšana

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

2026. g. 1. jūn. 17:18 UTC

Tirgus saruna

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

2026. g. 1. jūn. 17:18 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 1. jūn. 17:10 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

40.19% augšup

Prognoze 12 mēnešiem

Vidējais 62.75 USD 40.19%

Augstākais 66 USD

Zemākais 55 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

17 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.